CARDIOLOGY I BREAKOUT SESSIONS. May Lisbon PORTUGAL Hotel da Estrela. Atrial Fibrillation/ Venous TromboEmbolism

Similar documents
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE

DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING

Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised

Tackling atrial fibrillation the health economics evidence

Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:

8/16/2016. Disclosures. Is Uninterrupted OAC Standard of Care for AF Ablation? CHRS 2016, San Francisco. Risk of Stroke Peri-Ablation

Bayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation

requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group

PIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016

Managing Traditional and Contemporary Antithrombotic Therapy Principles and Practice: Practice Based Program

What s new with DOACs? Defining place in therapy for edoxaban &

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie

American College of Cardiology 66th Annual Scientific Session (ACC.17):

2015 Preliminary Agenda

Audit+ Atrial Fibrillation Module (beta V2.1) quick start guide To Review Therapy

Pharmaceutical Care of People with Atrial Fibrillation. Course information

Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016

Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation

Perioperative Management of Anticoagulation

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation

That the Single Commissioning Board supports the project outlined in this report and proceeds as described.

PRELIMINARY PROGRAMME

Rhona Maclean

18/09/2012. Dr. Khalid Khan Consultant Cardiologist BCUHB. Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham

Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)

Press Release. Page 1 of 6

DRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism

Anticoagulation, atrial fibrillation in elderly patients with chronic kidney disease

New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017

Atrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16

A Patient with Chest Pain and Atrial Fibrillation

New Study Presented at American Heart Association (AHA) Scientific Sessions 2016:

Practical Update in Cardiology 2017

The era of NOACs. (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul

Atrial fibrillation patient decision aid: Antithrombotic therapy

Invasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic

News Release. For UK Media

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis

Results from the ENSURE-AF study were presented during the ESC Congress 2016 Hot Line session and the full results are published in The Lancet

Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion

Atrial fibrillation and anticoagulation therapy

2018 Arrhythmia Symposium at the Cedars-Sinai Smidt Heart Institute

CLINICAL AUDIT. Renal Function Testing in People. Taking Dabigatran

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

Atrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today

National Institute for Health and Clinical Excellence Health Technology Appraisal

The introduction of dabigatran etexilate (Pradaxa )

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia

Program Director: Neala J. Hunter, MD, FACC

Agenda Item No. 8a SERVICE SPECIFICATION. 1. Introduction:

Initial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care

An Audit of the Post-Operative Management of Patients taking Warfarin

Rivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.

Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency

Management of Atrial Fibrillation in Friday, October 6, 2017 Seattle

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism

FRONTLINE CARDIOLOGY. APRIL 21, 2018 College Park Marriott Hotel & Conference Center Hyattsville, MD COURSE DIRECTORS: COURSE CO-DIRECTOR:

V Baltic Heart Failure Meeting and Arrhythmias Baltica October Bellevue Park Hotel Riga, 1 Slokas Street, Riga, Latvia Scientific Programme

Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)

Helping you take control

How to prevent thrombotic diseases? Sergio Fusco, MD

Anti-thromboticthrombotic drugs

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Southern Trust Anticoagulant Team

Management of new onset atrial fibrillation McNamara R L, Bass E B, Miller M R, Segal J B, Goodman S N, Kim N L, Robinson K A, Powe N R

Bios 6648: Design & conduct of clinical research

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD

HEART RHYTHM 2018 WORLD HEART RHYTHM CONFERENCE. Let s Explore the Rhythm of the Heart

4:30 p.m. Jack Vogel Memorial Lecture Evolution and Revolution in the Treatment of Valvular Heart Disease Dr. Mack

Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery

Management of Postoperative Atrial Fibrillation

CVI s New Paradigms in Arrhythmia Management 2012: Atrial Fibrillation to Sudden Death Sunday, April 22, 2012 Loews Philadelphia Hotel

Bayer AG Investor Relations Leverkusen Germany Investor News. Not intended for U.S. and UK Media

Catheter ablation: the recovery process and what to expect

Can the UK afford ablation for persistent AF? cost efficacy analysis. Dr Derick Todd Liverpool Heart & Chest Hospital

NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli

COMPREHENSIVE CV DISEASE MANAGEMENT:

Peri-cardioversion and peri-ablation anticoagulation. Giuseppe Patti Campus Bio-Medico University of Rome

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism

Clinical issues which drug for which patient

Post Reproductive Health Joint RCOG/BMS Meeting Wednesday 31 October _ Thursday 1 November 2018

Warfarin Atrial Fibrillation Consultations A Visual Support Tool

Supplementary Online Content

AHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke. Version: 13 March 2017

STROKE PREVENTION in ATRIAL FIBRILLATION

Do Not Cite. Draft for Work Group Review.

INTRODUCTION Indication and Licensing

2018 THERAPEUTICS UPDATE

Spontaneous Atrial Fibrillation and Noacs and Reversal agents

BDHP Chronic Disease Theme Forum

DIAGNOSTICS ASSESSMENT PROGRAMME

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

Transcription:

BREAKOUT SESSIONS CARDIOLOGY I Atrial Fibrillation/ Venous TromboEmbolism Advanced Clinical Knowledge for Pharmacists www.hcpa.pt

OUR EXPERTS Helen Williams MRPharmS PGDip(Cardiol) Ipresc \ Consultant Pharmacist for Cardiovascular Disease for South London Cardiac and Stroke Networks and Southwark Health and Social Care Network. Sotiris Antoniou FFRPS MRPharmS MSc Dip Mgt IPresc \ Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust.

WE WILL DISCUSS ABOUT CARDIOLOGY I Atrial Fibrillation/ Venous TromboEmbolism Atrial Fibrillation \ Understand the pathophysiology of atrial fibrillation and explain the importance of atrial fibrillation as a risk factor for stroke Venous Thromboembolism \ Understand the pathophysiology of venous thromboembolism and the implications of VTE for healthcare systems \ Discuss the key recommendations relating to AF -related stroke prevention in national and international guidelines \ Discuss the key recommendations relating to the treatment and prevention of VTE in national and international guidelines \ Apply the evidence base supporting the different pharmacological agents available to reduce stroke risk in Atrial Fibrillation to the care of individual patients \ Explain the benefits and risks of anticoagulation for stroke prevention in AF to : \ Other clinicians \ Patients \ Apply the evidence base supporting the different pharmacological agents available to treat VTE to the care of individual patients \ Understand the principles of VTE risk assessment and make recommendations regarding VTE prevention

AGENDA 9:00 am - 6:00pm CARDIOLOGY I Atrial Fibrillation/ Venous TromboEmbolism Atrial Fibrillation \ What is AF? \ Prevalence \ Impact on morbidity and mortality \ The local situation datasets \ Other important Risk factors \ Diagnosing AF Management \ The impact of AF-related stroke \ Stroke prevention strategies clinical evidence \ National and international guidelines \ Risk stratification using CHA2DS2VASc and HASBLED \ Choice of anticoagulant comparing anticoagulant options \ Optimising anticoagulation TTR, adherence \ What about aspirin in AF? \ Balancing benefit and risk - making difficult decisions \ Non-pharmacological options Management \ Rate and rhythm control \ Rate control drug choices \ Rhythm control drugs vs cardioversion vs ablation \ Monitoring anti-arrhythmic drug therapies Medicines Optimisation case studies Venous Thromboembolism \ What is VTE? \ Prevalence and Outcome \ The local situation datasets \ Diagnosing VTE Management \ VTE treatment strategies clinical evidence \ National and international guidelines \ Choice of anticoagulant comparing anticoagulant options - LMWH, VKA, NOACs \ What about aspirin in VTE? \ Initiation regimens role of heparin \ Duration of treatment \ Cancer and VTE \ Non-pharmacological options Medicines Optimisation case studies Issues With Anticoagulation Bridging for Surgery Switching agents Managing Bleeds Reversal and Antidotes Adherence

CONTACTS Co-Chairs Sotiris Antoniou Helen Williams Scientific Committee Sotiris Antoniou Helen Williams Fernando Fernandez-Llimos Organising Committee Andreia Duarte, HCPA Rui Rodrigues, HCPA To register or for further information, please contact the HCPA office Rua da Junqueira Nº200, 1º Andar, 10-346 Lisboa Portugal Tel: +351 213616720 Email hcpa@hcpa.pt Website www.hcpa.pt

SAVE THE DATE! Places are limited for 20 PARTICIPANTS don t delay, REGISTER TODAY! Registration Fee 750 (VAT included) Fee includes lunch cofee-breaks educational material -10% (registration 2 or more sessions)

BREAKOUT SESSIONS DELEGATE QUOTES from previous similar HCPA Breakout Sessions: The most valuable part: the take home messages that we can apply on our work places Speakers - excellent knowledge and communication skills The program focus the most important aspects in this area Meet the people Share knowledge Learn with the best WE RE LOOKING FORWARD TO SEE YOU!